Register      Login

VOLUME 2 , ISSUE 3 ( July-September, 2023 ) > List of Articles


Respiratory Syncytial Virus Infections in Neonates: A Persisting Problem

Ilhama Namazova, John T Benjamin, Yuping Wang

Keywords : Arexvy, Bronchiolitis, Lower respiratory tract infection, Neonate, Nerve growth factor/TrkA receptor axis, Newborn, Nirsevimab, Palivizumab, Perinatal RSV infection, Pneumoviridae

Citation Information : Namazova I, Benjamin JT, Wang Y. Respiratory Syncytial Virus Infections in Neonates: A Persisting Problem. 2023; 2 (3):222-234.

DOI: 10.5005/jp-journals-11002-0073

License: CC BY-NC 4.0

Published Online: 26-09-2023

Copyright Statement:  Copyright © 2023; The Author(s).


Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infections in young infants. It is an enveloped, single-stranded, nonsegmented, negative-strand RNA virus, a member of the family Pneumoviridae. Globally, RSV is responsible for 2.3% of deaths among neonates 0–27 days of age. Respiratory syncytial virus infection is most common in children aged below 24 months. Neonates present with cough and fever. Respiratory syncytial virus-associated wheezing is seen in 20% infants during the first year of life of which 2–3% require hospitalization. Reverse transcriptase polymerase chain reaction (RT-PCR) gives fast results and has higher sensitivity compared with culture and rapid antigen tests and are not affected by passively administered antibody to RSV. Therapy for RSV infection of the LRT is mainly supportive, and preventive measures like good hygiene and isolation are the mainstay of management. Standard precautions, hand hygiene, breastfeeding and contact isolation should be followed for RSV-infected newborns. Recent AAP guidelines do not recommend pavilizumab prophylaxis for preterm infants born at 29–35 weeks without chronic lung disease, hemodynamically significant congenital heart disease and coexisting conditions. RSV can lead to long-term sequelae such as wheezing and asthma, associated with increased healthcare costs and reduced quality of life.

PDF Share
  1. Chanock R, Roizman B, Myers R. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization. Am J Hyg 1957;66(3):281–290. DOI: 10.1093/oxfordjournals.aje.a119901.
  2. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009;360(6):588–598. DOI: 10.1056/NEJMOA0804877.
  3. Afonso CL, Amarasinghe GK, Bányai K, et al. Taxonomy of the order Mononegavirales: update 2016. Arch Virol 2016;161(8):2351–2360. DOI: 10.1007/S00705-016-2880-1/TABLES/1.
  4. Johansson C. Respiratory syncytial virus infection: an innate perspective. F1000Res 2016;5:2898. DOI: 10.12688/F1000RESEARCH. 9637.1.
  5. White LJ, Waris M, Cane PA, et al. The transmission dynamics of groups A and B human respiratory syncytial virus (hRSV) in England & Wales and Finland: seasonality and cross-protection. Epidemiol Infect 2005;133(2):279–289. DOI: 10.1017/S0950268804003450.
  6. Papadopoulos NG, Gourgiotis D, Javadyan A, et al. Does respiratory syncytial virus subtype influences the severity of acute bronchiolitis in hospitalized infants? Respir Med 2004;98(9):879–882. DOI: 10.1016/J.RMED.2004.01.009.
  7. Gilca R, de Serres G, Tremblay M, et al. Distribution and clinical impact of human respiratory syncytial virus genotypes in hospitalized children over 2 winter seasons. J Infect Dis 2006;193(1):54–58. DOI: 10.1086/498526.
  8. Walsh EE, McConnochie KM, Long CE, et al. Severity of respiratory syncytial virus infection is related to virus strain. J Infect Dis 1997;175(4):814–820. DOI:10.1086/513976.
  9. McConnochie KM, Hall CB, Walsh EE, et al. Variation in severity of respiratory syncytial virus infections with subtype. J Pediatr 1990;117(1 Pt 1):52–62. DOI: 10.1016/S0022-3476(05)82443-6.
  10. Hall CB, Walsh EE, Schnabel KC, et al. Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children. J Infect Dis 1990;162(6):1283–1290. DOI: 10.1093/INFDIS/162.6.1283.
  11. Stein RT, Bont LJ, Zar H, et al. Respiratory syncytial virus hospitalization and mortality: systematic review and meta-analysis. Pediatr Pulmonol 2017;52(4):556–569. DOI: 10.1002/PPUL.23570.
  12. Shi T, McAllister DA, O'Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet 2017;390(10098):946–958. DOI: 10.1016/S0140-6736(17)30938-8.
  13. Hall CB, Douglas RG, Geiman JM. Possible Transmission by Fomites of Respiratory Syncytial Virus. J Infect Dis 1980;141(1):98–102. DOI: 10.1093/INFDIS/141.1.98.
  14. Rezaee F, Linfield DT, Harford TJ, et al. Ongoing developments in RSV prophylaxis: a clinician's analysis. Curr Opin Virol 2017;24:70–78. DOI: 10.1016/J.COVIRO.2017.03.015.
  15. Munywoki PK, Koech DC, Agoti CN, et al. Influence of age, severity of infection, and co-infection on the duration of respiratory syncytial virus (RSV) shedding. Epidemiol Infect 2015;143(4):804–812. DOI: 10.1017/S0950268814001393.
  16. King JC, Burke AR, Clemens JD, et al. Respiratory syncytial virus illnesses in human immunodeficiency virus- and noninfected children. Pediatr Infect Dis J 1993;12(9):733–739. DOI: 10.1097/00006454-199309000-00006.
  17. Hall CB, Weinberg GA, Blumkin AK, et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics 2013;132(2). DOI:10.1542/PEDS.2013-0303.
  18. Rose EB, Wheatley A, Langley G, et al. Respiratory syncytial virus seasonality – United States, 2014–2017. MMWR Morb Mortal Wkly Rep 2018;67(2):71–76. DOI: 10.15585/MMWR.MM6702A4.
  19. Obando-Pacheco P, Justicia-Grande AJ, Rivero-Calle I, et al. Respiratory syncytial virus seasonality: a global overview. J Infect Dis 2018;217(9):1356–1364. DOI: 10.1093/INFDIS/JIY056.
  20. Olsen SJ, Winn AK, Budd AP, et al. Changes in Influenza and Other Respiratory Virus Activity During the COVID-19 Pandemic – United States, 2020–2021. MMWR Morb Mortal Wkly Rep 2021;70(29): 1013–1019. DOI: 10.15585/MMWR.MM7029A1.
  21. Haddadin Z, Schuster JE, Spieker AJ, et al. Acute Respiratory Illnesses in Children in the SARS-CoV-2 Pandemic: Prospective Multicenter Study. Pediatrics 2021;148(2): DOI: 10.1542/PEDS.2021-051462.
  22. Nolen LD, Seeman S, Bruden D, et al. Impact of social distancing and travel restrictions on non-coronavirus disease 2019 (Non-COVID-19) respiratory hospital admissions in young children in rural Alaska. Clin Infect Dis 2021;72(12):2196–2198. DOI: 10.1093/CID/CIAA1328.
  23. Friedrich F, Ongaratto R, Scotta MC, et al. Early impact of social distancing in response to coronavirus disease 2019 on hospitalizations for acute bronchiolitis in infants in Brazil. Clin Infect Dis 2021;72(12):2071–2075. DOI: 10.1093/CID/CIAA1458.
  24. Yeoh DK, Foley DA, Minney-Smith CA, et al. Impact of coronavirus disease 2019 public health measures on detections of influenza and respiratory syncytial virus in children during the 2020 Australian winter. Clin Infect Dis 2021;72(12):2199–2202. DOI: 10.1093/CID/CIAA1475.
  25. van Brusselen D, de Troeyer K, ter Haar E, et al. Bronchiolitis in COVID-19 times: a nearly absent disease? Eur J Pediatr 2021;180(6):1969–1973. DOI: 10.1007/S00431-021-03968-6.
  26. Agha R, Avner JR. Delayed seasonal RSV surge observed during the COVID-19 pandemic. Pediatrics 2021;148(3): DOI: 10.1542/PEDS.2021-052089.
  27. Perk Y, Özdil M. Respiratory syncytial virüs infections in neonates and infants. Turkish Archives of Pediatrics/Türk Pediatri Arşivi 2018;53(2):63. DOI: 10.5152/TURKPEDIATRIARS.2018.6939.
  28. Boyce TG, Mellen BG, Mitchel EF, et al. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr 2000;137(6):865–870. DOI: 10.1067/MPD.2000.110531.
  29. Simoes EAF. Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr 2003;143(5 SUPPL.). DOI: 10.1067/s0022-3476(03)00511-0.
  30. Houben ML, Bont L, Wilbrink B, et al. Clinical prediction rule for RSV bronchiolitis in healthy newborns: prognostic birth cohort study. Pediatrics 2011;127(1):35–41. DOI: 10.1542/PEDS.2010-0581.
  31. Munywoki PK, Koech DC, Agoti CN, et al. Frequent asymptomatic respiratory syncytial virus infections during an epidemic in a rural Kenyan household cohort. J Infect Dis 2015;212(11):1711–1718. DOI: 10.1093/INFDIS/JIV263.
  32. Sheridan-Pereira M, Murphy J, Sloan J, et al. Respiratory syncytial virus preterm (32–36 completed weeks of gestation) risk estimation measure for RSV hospitalization in Ireland: a prospective study. Pediatr Infect Dis J 2016;35(1):19–24. DOI: 10.1097/INF.0000000000000918.
  33. Mitchell I, Wong SK, Paes B, et al. Respiratory syncytial virus prophylaxis in cystic fibrosis: the Canadian registry of palivizumab data (2005–2016). Eur J Clin Microbiol Infect Dis 2018;37(7):1345–1352. DOI: 10.1007/S10096-018-3256-0.
  34. Manzoni P, Figueras-Aloy J, Simões EAF, et al. Defining the incidence and associated morbidity and mortality of severe respiratory syncytial virus infection among children with chronic diseases. Infect Dis Ther 2017;6(3):383–411. DOI: 10.1007/S40121-017-0160-3.
  35. Paes B, Fauroux B, Figueras-Aloy J, et al. Defining the risk and associated morbidity and mortality of severe respiratory syncytial virus infection among infants with chronic lung disease. Infect Dis Ther 2016;5(4):453–471. DOI: 10.1007/S40121-016-0137-7.
  36. Wang EEL, Law BJ, Boucher FD, et al. Pediatric investigators collaborative network on infections in Canada (PICNIC) study of admission and management variation in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr 1996;129(3):390–395. DOI: 10.1016/S0022-3476(96)70071-9.
  37. Gijtenbeek RGP, Kerstjens JM, Reijneveld SA, et al. RSV infection among children born moderately preterm in a community-based cohort. Eur J Pediatr 2015;174(4):435–442. DOI: 10.1007/S00431-014-2415-2.
  38. Welliver RC, Checchia PA, Bauman JH, et al. Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy children. Curr Med Res Opin 2010;26(9):2175–2181. DOI: 10.1185/03007995.2010.505126.
  39. Checchia PA, Paes B, Bont L, et al. Defining the risk and associated morbidity and mortality of severe respiratory syncytial virus infection among infants with congenital heart disease. Infect Dis Ther 2017;6(1):37–56. DOI: 10.1007/S40121-016-0142-X.
  40. von Linstow ML, Høgh M, Nordbø SA, et al. A community study of clinical traits and risk factors for human metapneumovirus and respiratory syncytial virus infection during the first year of life. Eur J Pediatr 2008;167(10):1125–1133. DOI: 10.1007/S00431-007-0643-4.
  41. Bradley JP, Bacharier LB, Bonfiglio JA, et al. Severity of respiratory syncytial virus bronchiolitis is affected by cigarette smoke exposure and atopy. Pediatrics 2005;115(1). DOI: 10.1542/PEDS.2004-0059.
  42. Maedel C, Kainz K, Frischer T, et al. Increased severity of respiratory syncytial virus airway infection due to passive smoke exposure. Pediatr Pulmonol 2018;53(9):1299–1306. DOI: 10.1002/PPUL.24137.
  43. Jallow S, Agosti Y, Kgagudi P, et al. Impaired transplacental transfer of respiratory syncytial virus-neutralizing antibodies in human immunodeficiency virus-infected versus -uninfected pregnant women. Clin Infect Dis 2019;69(1):151–154. DOI: 10.1093/CID/CIY1071.
  44. Cohen C, Moyes J, Tempia S, et al. Epidemiology of acute lower respiratory tract infection in HIV-exposed uninfected infants. Pediatrics 2016;137(4). DOI: 10.1542/PEDS.2015-3272.
  45. Weinberg A, Mussi-Pinhata MM, Yu Q, et al. Excess respiratory viral infections and low antibody responses among HIV-exposed, uninfected infants. AIDS 2017;31(5):669–679. DOI: 10.1097/QAD.0000000000001393.
  46. Beckhaus AA, Castro-Rodriguez JA. Down syndrome and the risk of severe RSV infection: a meta-analysis. Pediatrics 2018;142(3): e20180225. DOI: 10.1542/PEDS.2018-0225.
  47. Shi T, Balsells E, Wastnedge E, et al. Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: systematic review and meta-analysis. J Glob Health 2015;5(2): 020416. DOI: 10.7189/JOGH.05.020416.
  48. Lanari M, Silvestri M, Rossi GA. Respiratory syncytial virus risk factors in late preterm infants. 2009;22(SUPPL. 3):102–107. DOI: 10.1080/14767050903194438.
  49. Choi EH, Lee HJ, Yoo T, Chanock SJ. A common haplotype of interleukin-4 gene IL4 is associated with severe respiratory syncytial virus disease in Korean children. J Infect Dis 2002;186(9):1207–1211. DOI: 10.1086/344310.
  50. Hoebee B, Rietveld E, Bont L, et al. Association of severe respiratory syncytial virus bronchiolitis with interleukin-4 and interleukin-4 receptor alpha polymorphisms. J Infect Dis 2003;187(1):2–11. DOI: 10.1086/345859.
  51. Goetghebuer T, Isles K, Moore C, et al. Genetic predisposition to wheeze following respiratory syncytial virus bronchiolitis. Clin Exp Allergy 2004;34(5):801–803. DOI: 10.1111/J.1365-2222.2004.1947.X.
  52. Hoebee B, Bont L, Rietveld E, et al. Influence of promoter variants of interleukin-10, interleukin-9, and tumor necrosis factor-alpha genes on respiratory syncytial virus bronchiolitis. J Infect Dis 2004;189(2):239–247. DOI: 10.1086/380908.
  53. Hull J, Rowlands K, Lockhart E, et al. Variants of the chemokine receptor CCR5 are associated with severe bronchiolitis caused by respiratory syncytial virus. J Infect Dis 2003;188(6):904–907. DOI: 10.1086/377587.
  54. Puthothu B, Krueger M, Forster J, et al. Association between severe respiratory syncytial virus infection and IL13/IL4 haplotypes. J Infect Dis 2006;193(3):438–441. DOI: 10.1086/499316.
  55. Löfgren J, Rämet M, Renko M, et al. Association between surfactant protein A gene locus and severe respiratory syncytial virus infection in infants. J Infect Dis 2002;185(3):283–289. DOI: 10.1086/338473.
  56. Lahti M, Löfgren J, Marttila R, et al. Surfactant protein D gene polymorphism associated with severe respiratory syncytial virus infection. Pediatr Res 2002;51(6):696–699. DOI: 10.1203/00006450-200206000-00006.
  57. Tal G, Mandelberg A, Dalal I, et al. Association between common Toll-like receptor 4 mutations and severe respiratory syncytial virus disease. J Infect Dis 2004;189(11):2057–2063. DOI: 10.1086/420830.
  58. Amanatidou V, Sourvinos G, Apostolakis S, et al. T280M variation of the CX3C receptor gene is associated with increased risk for severe respiratory syncytial virus bronchiolitis. Pediatr Infect Dis J 2006;25(5):410–414. DOI: 10.1097/01.INF.0000214998.16248.B7.
  59. El Saleeby CM, Li R, Somes GW, et al. Surfactant protein A2 polymorphisms and disease severity in a respiratory syncytial virus-infected population. J Pediatr 2010;156(3): 409–414. DOI: 10.1016/J.JPEDS.2009.09.043.
  60. López EL, Ferolla FM, Toledano A, et al. Genetic Susceptibility to life-threatening respiratory syncytial virus infection in previously healthy infants. Pediatr Infect Dis J 2020;39(11):1057–1061. DOI: 10.1097/INF.0000000000002827.
  61. Battles MB, McLellan JS. Respiratory syncytial virus entry and how to block it. Nature Rev Microbiol 2019;17(4):233–245. DOI: 10.1038/s41579-019-0149-x.
  62. Mohapatra SS, Lockey RF. Respiratory syncytial virus infection: from biology to therapy a perspective. World Allergy Organ J 2008;1(2):21. DOI: 10.1097/WOX.0B013E31816549A2.
  63. McLellan JS, Ray WC, Peeples ME. Structure and function of RSV surface glycoproteins. Curr Top Microbiol Immunol 2013;372:83. DOI: 10.1007/978-3-642-38919-1_4.
  64. Johnson SM, McNally BA, Ioannidis I, et al. Respiratory Syncytial Virus Uses CX3CR1 as a Receptor on Primary Human Airway Epithelial Cultures. PLoS Pathog 2015;11(12):e1005318. DOI: 10.1371/JOURNAL.PPAT.1005318.
  65. Fleming EH, Kolokoltsov AA, Davey RA, et al. Respiratory Syncytial Virus F Envelope protein associates with lipid rafts without a requirement for other virus proteins. J Virol 2006;80(24):12160–12170. DOI: 10.1128/JVI.00643-06.
  66. Guo X, Liu T, Shi H, et al. Respiratory syncytial virus infection upregulates NLRC5 and major histocompatibility complex class I expression through RIG-I induction in airway epithelial cells. J Virol 2015;89(15):7636–7645. DOI: 10.1128/JVI.00349-15.
  67. Schlender J, Zimmer G, Herrler G, et al. Respiratory syncytial virus (RSV) fusion protein subunit F2, not attachment protein G, determines the specificity of RSV infection. J Virol 2003;77(8):4609. DOI: 10.1128/JVI.77.8.4609-4616.2003.
  68. Tiwari PM, Eroglu E, Boyoglu-Barnum S, et al. Atomic force microscopic investigation of respiratory syncytial virus infection in HEp-2 cells. J Microsc 2014;253(1):31. DOI: 10.1111/JMI.12095.
  69. Efstathiou C, Abidi SH, Harker J, et al. Revisiting respiratory syncytial virus's interaction with host immunity, towards novel therapeutics. Cell Mol Life Sci 2020;77(24):5045. DOI: 10.1007/S00018-020-03557-0.
  70. Zhao X, Singh M, Malashkevich VN, et al. Structural characterization of the human respiratory syncytial virus fusion protein core. Proc Natl Acad Sci U S A 2000;97(26):14172. DOI: 10.1073/PNAS.260499197.
  71. Shahriari S, Wei KJ, Ghildyal R. Respiratory syncytial virus matrix (M) protein interacts with actin in vitro and in cell culture. Viruses 2018;10(10). DOI: 10.3390/V10100535.
  72. Cao D, Gao Y, Liang B. Structural insights into the respiratory syncytial virus RNA synthesis complexes. Viruses 2021;13(5). DOI: 10.3390/V13050834.
  73. Sutto-Ortiz P, Tcherniuk S, Ysebaert N, et al. The methyltransferase domain of the respiratory syncytial virus L protein catalyzes cap N7 and 2’-O-methylation. PLoS Pathog 2021;17(5):e1009562. DOI: 10.1371/JOURNAL.PPAT.1009562.
  74. Cervantes-Ortiz SL, Cuervo NZ, Grandvaux N. Respiratory syncytial virus and cellular stress responses: impact on replication and physiopathology. Viruses 2016;8(5): 124. DOI:10.3390/V8050124.
  75. Whelan SPJ, Barr JN, Wertz GW. Transcription and replication of nonsegmented negative-strand RNA viruses. Curr Top Microbiol Immunol 2004;283:61–119. DOI: 10.1007/978-3-662-06099-5_3.
  76. Paes B, Fullarton JR, Rodgers-Gray BS, et al. Adoption in Canada of an international risk scoring tool to predict respiratory syncytial virus hospitalization in moderate-to-late preterm infants. Curr Med Res Opin 2021;37(7):1149–1153. DOI: 10.1080/03007995.2021.191 1974.
  77. Ák ZS, Saliba E, Kosma P, et al. Predictors of RSV LRTI Hospitalization in Infants Born at 33 to 35 weeks gestational age: a large multinational study (PONI). PLoS One 2016;11(6): e0157446. DOI: 10.1371/JOURNAL.PONE.0157446.
  78. Figueras-Aloy J, Carbonell-Estrany X, Quero-Jiménez J, et al. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J 2008;27(9):788–793. DOI: 10.1097/INF.0B013E3181710990.
  79. Ambrose CS, Anderson EJ, Simões EAF, et al. Respiratory syncytial virus disease in preterm infants in the U.S. born at 32–35 weeks gestation not receiving immunoprophylaxis. Pediatr Infect Dis J 2014;33(6):576–582. DOI: 10.1097/INF.0000000000000219.
  80. Waycaster G, Vo P, Deaton R, et al. Respiratory syncytial virus-related hospitalization in premature infants without bronchopulmonary dysplasia: subgroup efficacy analysis of the IMpact-RSV trial by gestational age group. Pediatric Health Med Ther. Published online May 2014:43. DOI: 10.2147/PHMT.S59572.
  81. Anderson EJ, Carbonell-Estrany X, Blanken M, et al. Burden of severe respiratory syncytial virus disease among 33–35 weeks’ gestational age infants born during multiple respiratory syncytial virus seasons. Pediatr Infect Dis J 2017;36(2):160–167. DOI: 10.1097/INF.0000000000001377.
  82. Blanken MO, Paes B, Anderson EJ, et al. Risk scoring tool to predict respiratory syncytial virus hospitalisation in premature infants. Pediatr Pulmonol 2018;53(5):605–612. DOI: 10.1002/PPUL.23960.
  83. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 1998;102(3 Pt 1):531–537. PMID: 9738173.
  84. Simoes EA, Groothuis JR. Respiratory syncytial virus prophylaxis--the story so far. Respir Med 2002;96 Suppl B:S15–S24. DOI: 10.1016/S0954-6111(02)90066-1.
  85. Piedimonte G, Walton C, Samsell L. Vertical transmission of respiratory syncytial virus modulates pre- and postnatal innervation and reactivity of rat airways. PLoS One 2013;8(4):e61309. DOI: 10.1371/journal.pone.0061309.
  86. Piedimonte G, Harford TJ. Effects of maternal-fetal transmission of viruses and other environmental agents on lung development. Pediatr Res 2020;87(2):420–426. DOI: 10.1038/S41390-019-0657-4.
  87. Rezaee F, Gibson LF, Piktel D, et al. Respiratory syncytial virus infection in human bone marrow stromal cells. Am J Respir Cell Mol Biol 2011;45(2):277–286. DOI: 10.1165/RCMB.2010-0121OC.
  88. Scuri M, Samsell L, Piedimonte G. The role of neurotrophins in inflammation and allergy. Inflamm Allergy Drug Targets 2010;9(3):173–180. DOI: 10.2174/187152810792231913.
  89. Lindsay RM, Harmar AJ. Nerve growth factor regulates expression of neuropeptide genes in adult sensory neurons. Nature 1989;337(6205):362–364. DOI: 10.1038/337362A0.
  90. Bonini S, Lambiase A, Bonini S, et al. Circulating nerve growth factor levels are increased in humans with allergic diseases and asthma. Proc Natl Acad Sci U S A 1996;93(20):10955–10960. DOI: 10.1073/PNAS.93.20.10955.
  91. Braun A, Lommatzsch M, Lewin GR, et al. Neurotrophins: a link between airway inflammation and airway smooth muscle contractility in asthma? Int Arch Allergy Immunol 1999;118(2–4): 163–165. DOI: 10.1159/000024056.
  92. Othumpangat S, Gibson LF, Samsell L, et al. NGF is an essential survival factor for bronchial epithelial cells during respiratory syncytial virus infection. PLoS One 2009;4(7). DOI: 10.1371/JOURNAL.PONE.0006444.
  93. Lambert L, Sagfors AM, Openshaw PJM, et al. Immunity to RSV in early-life. Front Immunol 2014;5(SEP). DOI: 10.3389/FIMMU.2014.00466.
  94. Russell CD, Unger SA, Walton M, et al. The human immune response to respiratory syncytial virus infection. Clin Microbiol Rev 2017;30(2):481–502. DOI: 10.1128/CMR.00090-16.
  95. Hall CB, Walsh EE, Long CE, et al. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 1991;163(4):693–698. DOI: 10.1093/INFDIS/163.4.693.
  96. Henderson FW, Collier AM, Clyde WA, et al. Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children. N Engl J Med 1979;300(10):530–534. DOI: 10.1056/NEJM197903083001004.
  97. Glezen WP, Paredes A, Allison JE, et al. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr 1981;98(5):708–715. DOI: 10.1016/S0022-3476(81)80829-3.
  98. Stensballe LG, Ravn H, Kristensen K, et al. Seasonal variation of maternally derived respiratory syncytial virus antibodies and association with infant hospitalizations for respiratory syncytial virus. J Pediatr 2009;154(2). DOI:10.1016/J.JPEDS.2008.07.053.
  99. Hoffman SJ, Laham FR, Polack FP. Mechanisms of illness during respiratory syncytial virus infection: The lungs, the virus and the immune response. Microbes Infect 2004;6(8):767–772. DOI: 10.1016/j.micinf.2004.03.010.
  100. Johnson JE, Gonzales RA, Olson SJ, et al. The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol 2007;20(1):108–119. DOI: 10.1038/MODPATHOL.3800725.
  101. Aherne W, Bird T, Court SD, et al Pathological changes in virus infections of the lower respiratory tract in children. J Clin Pathol 1970;23(1):7–18. DOI: 10.1136/JCP.23.1.7.
  102. Everard ML, Swarbrick A, Wrightham M, et al. Analysis of cells obtained by bronchial lavage of infants with respiratory syncytial virus infection. Arch Dis Child 1994;71(5):428–432. DOI: 10.1136/ADC.71.5.428.
  103. Nadal D, Wunderli W, Meurmann O, et al. Isolation of respiratory syncytial virus from liver tissue and extrahepatic biliary atresia material. Scand J Infect Dis 1990;22(1):91–93. DOI: 10.3109/00365549009023125.
  104. Zlateva KT, van Ranst M. Detection of subgroup B respiratory syncytial virus in the cerebrospinal fluid of a patient with respiratory syncytial virus pneumonia. Pediatr Infect Dis J 2004;23(11):1065–1066. DOI: 10.1097/01.INF.0000143654.12493.C9.
  105. Fishaut M, Tubergen D, McIntosh K. Cellular response to respiratory viruses with particular reference to children with disorders of cell-mediated immunity. J Pediatr 1980;96(2):179–186. DOI: 10.1016/S0022-3476(80)80799-2.
  106. Noah TL, Henderson FW, Wortman IA, et al. Nasal cytokine production in viral acute upper respiratory infection of childhood. J Infect Dis 1995;171(3):584–592. DOI: 10.1093/INFDIS/171.3.584.
  107. Matsuda K, Tsutsumi H, Okamoto Y, et al. Development of interleukin 6 and tumor necrosis factor alpha activity in nasopharyngeal secretions of infants and children during infection with respiratory syncytial virus. Clin Diagn Lab Immunol 1995;2(3):322–324. DOI: 10.1128/CDLI.2.3.322-324.1995.
  108. Smyth RL, Fletcher JN, Thomas HM, et al. Immunological responses to respiratory syncytial virus infection in infancy. Arch Dis Child 1997;76(3):210–214. DOI: 10.1136/ADC.76.3.210.
  109. Garofalo RP, Patti J, Hintz KA, et al. Macrophage inflammatory protein-1alpha (not T helper type 2 cytokines) is associated with severe forms of respiratory syncytial virus bronchiolitis. J Infect Dis 2001;184(4):393–399. DOI: 10.1086/322788.
  110. Welliver RC, Garofalo RP, Ogra PL. Beta-chemokines, but neither T helper type 1 nor T helper type 2 cytokines, correlate with severity of illness during respiratory syncytial virus infection. Pediatr Infect Dis J 2002;21(5):457–461. DOI: 10.1097/00006454-200205000-00033.
  111. Garofalo RP, Hintz KH, Hill V, et al. A comparison of epidemiologic and immunologic features of bronchiolitis caused by influenza virus and respiratory syncytial virus. J Med Virol 2005;75(2):282–289. DOI: 10.1002/JMV.20268.
  112. Tregoning JS, Schwarze J. Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clin Microbiol Rev 2010;23(1):74–98. DOI: 10.1128/CMR.00032-09.
  113. Ralston S, Hill V. Incidence of apnea in infants hospitalized with respiratory syncytial virus bronchiolitis: a systematic review. J Pediatr 2009;155(5): 728–733. DOI:10.1016/J.JPEDS.2009.04.063.
  114. Leo Arms J, Ortega H, Reid S. Chronological and clinical characteristics of apnea associated with respiratory syncytial virus infection: a retrospective case series. Clin Pediatr (Phila) 2008;47(9):953–958. DOI: 10.1177/0009922808320699.
  115. Hall CB, Hall WJ, Speers DM. Clinical and physiological manifestations of bronchiolitis and pneumonia. Outcome of respiratory syncytial virus. Am J Dis Child 1979;133(8):798–802. DOI: 10.1001/ARCHPEDI.1979.02130080038006.
  116. Church NR, Anas NG, Hall CB, et al. Respiratory syncytial virus-related apnea in infants. Demographics and outcome. Am J Dis Child 1984;138(3):247–250. DOI: 10.1001/ARCHPEDI.1984.02140410027010.
  117. Bruhn FW, Mokrohisky ST, McIntosh K. Apnea associated with respiratory syncytial virus infection in young infants. J Pediatr 1977;90(3):382–386. DOI: 10.1016/S0022-3476(77)80697-5.
  118. Anas N, Boettrich C, Hall CB, et al. The association of apnea and respiratory syncytial virus infection in infants. J Pediatr 1982;101(1):65–69. DOI: 10.1016/S0022-3476(82)80184-4.
  119. Lindgren C, Jing L, Graham B, et al. Respiratory syncytial virus infection reinforces reflex apnea in young lambs. Pediatr Res 1992;31(4 Pt 1):381–385. DOI: 10.1203/00006450-199204000-00015.
  120. Murray J, Bottle A, Sharland M, et al. Risk factors for hospital admission with RSV bronchiolitis in England: a population-based birth cohort study. PLoS One 2014;9(2). DOI: 10.1371/JOURNAL.PONE.0089186.
  121. Hervás D, Reina J, Yañez A, et al. Epidemiology of hospitalization for acute bronchiolitis in children: differences between RSV and non-RSV bronchiolitis. Eur J Clin Microbiol Infect Dis 2012;31(8):1975–1981. DOI: 10.1007/S10096-011-1529-Y
  122. O'Brien KL, Baggett HC, Brooks WA, et al. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study. Lancet 2019;394(10200):757–779. DOI: 10.1016/S0140-6736(19)30721-4.
  123. Glezen WP, Taber LH, Frank AL, et al. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986;140(6):543–546. DOI: 10.1001/ARCHPEDI.1986.02140200053026.
  124. Hall CB, Long CE, Schnabel KC. Respiratory syncytial virus infections in previously healthy working adults. Clin Infect Dis 2001;33(6):792–796. DOI: 10.1086/322657.
  125. Rady MY, Johnson DJ, Patel B, et al. Extrapulmonary manifestations of severe respiratory syncytial virus infection – a systematic review. Crit Care 2006;10(4):R107. DOI: 10.1186/CC4984.
  126. Hanna S, Tibby SM, Durward A, et al. Incidence of hyponatraemia and hyponatraemic seizures in severe respiratory syncytial virus bronchiolitis. Acta Paediatr 2003;92(4):430–434. DOI: 10.1111/J.1651-2227.2003.TB00573.X.
  127. van Steensel-Moll HA, Hazelzet JA, van der Voort E, et al. Excessive secretion of antidiuretic hormone in infections with respiratory syncytial virus. Arch Dis Child 1990;65(11):1237–1239. DOI: 10.1136/ADC.65.11.1237.
  128. Berry CE, Billheimer D, Jenkins IC, et al. A Distinct low lung function trajectory from childhood to the fourth decade of life. Am J Respir Crit Care Med 2016;194(5):607–612. DOI: 10.1164/RCCM.201604-0753OC.
  129. Overview: Bronchiolitis in children: diagnosis and management. Guidance NICE.
  130. Ginocchio CC, McAdam AJ. Current best practices for respiratory virus testing. J Clin Microbiol 2011;49(9 Suppl):S44. DOI: 10.1128/JCM.00698-11.
  131. Deming DJ, Patel N, McCarthy MP, et al. Potential for palivizumab interference with commercially available antibody-antigen based respiratory syncytial virus diagnostic assays. Pediatr Infect Dis J 2013;32(10):1144–1146. DOI: 10.1097/INF.0B013E31829561DD.
  132. Chartrand C, Tremblay N, Renaud C, et al. Diagnostic Accuracy of Rapid Antigen Detection Tests for Respiratory Syncytial Virus Infection: Systematic Review and Meta-analysis. J Clin Microbiol 2015;53(12):3738–3749. DOI: 10.1128/JCM.01816-15.
  133. Somerville LK, Mala Ratnamohan V, Dwyer DE, et al. Molecular diagnosis of respiratory viruses. Pathology 2015;47(3):243. DOI: 10.1097/PAT.0000000000000240.
  134. Puppe W, Weigl JAI, Aron G, et al. Evaluation of a multiplex reverse transcriptase PCR ELISA for the detection of nine respiratory tract pathogens. J Clin Virol 2004;30(2):165–174. DOI: 10.1016/j.jcv.2003.10.003.
  135. Vos LM, Bruning AHL, Reitsma JB, et al. Rapid molecular tests for influenza, respiratory syncytial virus, and other respiratory viruses: a systematic review of diagnostic accuracy and clinical impact studies. Clin Infect Dis 2019;69(7):1243–1253. DOI: 10.1093/CID/CIZ056.
  136. Miller JM, Binnicker MJ, Campbell S, et al. A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2018 update by the Infectious Diseases Society of America and the American Society for Microbiology. Clin Infect Dis 2018;67(6):e1–e94. DOI: 10.1093/CID/CIY381.
  137. Allen KE, Chommanard C, Haynes AK et al. Respiratory syncytial virus testing capabilities and practices among National Respiratory and Enteric Virus Surveillance System Laboratories, United States, 2016. J Clin Virol 2018;107:48–51. DOI: 10.1016/J.JCV.2018.08.009.
  138. Jorquera PA, Tripp RA. Respiratory syncytial virus: prospects for new and emerging therapeutics. Expert Rev Respir Med 2017;11(8): 609–615. DOI: 10.1080/17476348.2017.1338567.
  139. Kodama F, Nace DA, Jump RLP. Respiratory syncytial virus and other noninfluenza respiratory viruses in older adults. Infect Dis Clin North Am 2017;31(4):767–790. DOI: 10.1016/J.IDC.2017.07.006.
  140. Ventre K, Randolph A. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. Cochrane Database Syst Rev 2004;(4). DOI: 10.1002/14651858.CD000181.PUB2.
  141. Ottolini MG, Hemming VG. Prevention and treatment recommendations for respiratory syncytial virus infection. Background and clinical experience 40 years after discovery. Drugs 1997;54(6):867–884. DOI: 10.2165/00003495-199754060-00006.
  142. Shah JN, Chemaly RF. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood 2011;117(10):2755–2763. DOI: 10.1182/BLOOD-2010-08-263400.
  143. Hirsch HH, Martino R, Ward KN, et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis and treatment of human respiratory syncytial virus, parainfluenza virus, metapneumovirus, rhinovirus, and coronavirus. Clin Infect Dis 2013;56(2):258–266. DOI: 10.1093/CID/CIS844.
  144. Krilov LR. Safety issues related to the administration of ribavirin. Pediatr Infect Dis J 2002;21(5):479–481. DOI: 10.1097/00006454-200205000-00037.
  145. Manuel O, Estabrook M. RNA respiratory viral infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019;33(9). DOI: 10.1111/CTR.13511.
  146. Roberts SS, Miller RK, Jones JK, et al. The Ribavirin Pregnancy Registry: Findings after 5 years of enrollment, 2003–2009. Birth Defects Res A Clin Mol Teratol 2010;88(7):551–559. DOI: 10.1002/BDRA. 20682.
  147. OSHA Technical Manual (OTM) – Section VI: Chapter 1: Occupational Safety and Health Administration. Accessed January 15, 2023.
  148. Hall CB, McBride JT, Walsh EE, et al. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. N Engl J Med 1983;308(24):1443–1447. DOI: 10.1056/NEJM198306163082403.
  149. Rodriguez WJ, Kim HW, Brandt CD, et al. Aerosolized ribavirin in the treatment of patients with respiratory syncytial virus disease. Pediatr Infect Dis J 1987;6(2):159–163. DOI: 10.1097/00006454-198702000-00004.
  150. Smith DW, Frankel LR, Mathers LH, et al. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med 1991;325(1):24–29. DOI: 10.1056/NEJM199107043250105.
  151. Taber LH, Knight V, Gilbert BE, et al. Ribavirin aerosol treatment of bronchiolitis associated with respi
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.